Following the exodus at Immunocore, Eliot Forster takes the reins at F-star — how long before the crossover and an IPO?
LONDON — Over the past 12 years, F-star has built up a rep for antibody design work that’s garnered the avid attention of a lineup of both big and remarkable development partners. But aside from the deals it’s done, and the milestones it’s been racking up, the Cambridge biotech never raised much cash for its operations from investors.
Employee #99, though, may just do something about that.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
